Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference
21 September 2017 - 6:30AM
Celyad (Euronext Brussels:CYAD) (Euronext
Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and
development of CAR-T cell therapies, today announced that Patrick
Jeanmart, Chief Financial Officer and David Gilham, VP Research and
Development of Celyad will present a corporate update at the
upcoming Cantor Fitzgerald Global Healthcare Conference on
Wednesday, September 27th, 2017 at 2:15 p.m. ET in New York, NY.
A live audio webcast of the presentation will be
available on the Investor Relations section of Celyad’s website
at www.celyad.com/en/investors, where it will be archived for
approximately 90 days.
About Celyad
Celyad is a clinical-stage biopharmaceutical
company focused on the development of specialized CAR-T cell based
therapies. Celyad utilizes its expertise in cell engineering to
target cancer. Celyad’s Natural Killer Receptor based T-Cell
(NKR-T) platform has the potential to treat a broad range of solid
and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T
NKG2D), has been evaluated in a single dose escalation Phase I
clinical trial to assess the safety and clinical activity of
multiple administrations of autologous CYAD-01 cells in seven
refractory cancers including five solid tumors (colorectal,
ovarian, bladder, triple-negative breast and pancreatic cancers)
and two hematological tumors (acute myeloid leukemia and multiple
myeloma). Celyad was founded in 2007 and is based in
Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s
ordinary shares are listed on the Euronext Brussels and Euronext
Paris exchanges, and its American Depository Shares are listed on
the NASDAQ Global Market, all under the ticker symbol CYAD.
For more information about Celyad, please visit:
www.celyad.com
For more information, please
contact:
For Europe: Consilium Strategic Communications
Chris Gardner and Chris Welsh
- T: +44 (0)20 3709 5700 –
celyad@consilium-comms.com |
For France: NewCapPierre
Laurent and Nicolas Mérigeau - T: +
33(0)1 44 71 94 94 - celyad@newcap.eu |
For Belgium: ComfiGunther De
Backer and Sabine Leclercq - T.: +32 (0)2
290 90 90 – celyad@comfi.be |
For the U.S.: Stern Investor RelationsWill
O’Connor and Michael Schaffzin – T.: +1
212.362.1200 – celyad@sternir.com |
To subscribe to Celyad’s newsletter,
visit www.celyad.comFollow us on LinkedIn &
Twitter @CelyadSA
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Apr 2024 to May 2024
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From May 2023 to May 2024